NCT05774665View on ClinicalTrials.gov

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

April 30, 2026

Conditions
Treatment Resistant DepressionInflammationOverweight
Interventions
DRUG

Omega 3

Omega-3 fatty acid enriched for eicosapentaenoic acid (EPA)

OTHER

Placebo

Placebo consisting of soybean oil (about 54% omega-6 and 6% omega-3, but no EPA or docosahexaenoic acid (DHA)).

Trial Locations (3)

30322

RECRUITING

Emory University School of Medicine, Atlanta

84108

RECRUITING

University of Utah, Salt Lake City

02114

RECRUITING

Depression Clinical and Research Program at Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

University of Utah

OTHER

collaborator

Emory University

OTHER

lead

Massachusetts General Hospital

OTHER